Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: Recommendations from a multidisciplinary panel

Hum Vaccin Immunother. 2024 Dec 31;20(1):2388943. doi: 10.1080/21645515.2024.2388943. Epub 2024 Aug 19.

Abstract

Respiratory syncytial virus (RSV) is an important cause of respiratory illness. While most attention is paid to childhood infection, the RSV burden in adults ≥60 y should also be considered. In Brazil, this is generally underrecognized, where greater focus is toward other respiratory pathogens. This article presents insights from a multidisciplinary panel gathered to review epidemiologic data and current diagnostic approaches to RSV in Brazil (and their limitations) and develop communication strategies to improve knowledge and awareness. National surveillance data indicate a steady increase in cases of RSV-related severe acute respiratory illness (RSV-SARI) in those aged ≥60 y in recent years, with high fatality rates (>30%). Routine RSV testing in older individuals with respiratory symptoms is relatively low. Educational activities targeted toward health-care professionals and the general public are critical to raising awareness of the importance of RSV in older individuals, particularly as protective vaccines are now available.

Keywords: Brazil; RSV; Respiratory syncytial virus; disease burden; older adults.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brazil / epidemiology
  • Humans
  • Middle Aged
  • Respiratory Syncytial Virus Infections* / diagnosis
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus, Human*

Grants and funding

The initial advisory board meeting, related study/research and subsequent manuscript development were sponsored by GlaxoSmithKline Biologicals SA. Support for third-party writing assistance and the Rapid Service and open access fees for this article were also funded by GlaxoSmithKline Biologicals SA in accordance with Good Publication Practice (GPP 2022) guidelines.